Market›Health Care›Pharmaceuticals›Pharmaceuticals
AARDVARK THERAPEUTIC

AARD

$5.39Feb 13, 2025 – Apr 24, 2026
Health CarePharmaceuticals$86M
MVM
-$0.1M
TD Variance
-18.000

Every news event mapped to its market reaction — 75 events, 15 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-03-02-59.9%newsInvestor's Business DailyWhy Aardvark Therapeutics Just Lost More Than Half Its Value
2026-03-02-59.9%legalMT NewswiresSector Update: Health Care Stocks Retreat Late Afternoon
2026-03-02-59.9%legalMT NewswiresSector Update: Health Care
2026-03-02-59.9%newsMT NewswiresTop Midday Decliners
2026-03-02-59.9%newsInvesting.comAardvark Therapeutics stock plunges after trial pause - Investing.com
2026-03-02-59.9%newsInvestor's Business DailyBiotech Stock Crashes 50%-Plus. What Happened? - Investor's Business Daily
2026-03-02-59.9%analystInvesting.comRBC Capital downgrades Aardvark Therapeutics stock rating on trial pause - Investing.com
2026-03-02-59.9%newsTipRanksWhy Is Aardvark Therapeutics Stock (AARD) Down Today? - TipRanks
2026-03-02-59.9%analystInvesting.comAardvark Therapeutics stock price target cut to $9 by BTIG on trial pause - Investing.com
2026-03-02-59.9%analystStocktwitsAARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
2026-03-02-59.9%analystInvesting.comMorgan Stanley downgrades Aardvark Therapeutics stock rating on trial pause - Investing.com
2026-03-02-59.9%analystInvesting.comBofA cuts Aardvark Therapeutics stock price target on trial pause - Investing.com
2026-03-02-59.9%newsEndpoints NewsAardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC - Endpoints News
2026-03-02-59.9%analystBenzingaThis Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Aardvark Therapeut - Benzinga
2026-03-02-59.9%analystBenzingaTwilio To Rally More Than 32%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
2026-02-28-56.3%legalBusiness WireAARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
2026-02-27-55.8%newsStocktwitsAardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
2025-09-12+27.2%legalTradingViewAardvark Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
2025-12-02+24.8%newsInvesting.comRaymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com
2026-03-04+17.0%newsSimply Wall St.Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions
2026-03-04+17.0%newsYahoo FinanceA Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial - Yahoo Finance
2026-03-20-16.4%newsBenzinga12 Health Care Stocks Moving In Friday's Intraday Session - Aardvark Therapeutics (NASDAQ:AARD), Azitra - Benzinga
2025-03-14-14.5%newsYahoo FinanceAardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Yahoo Finance
2025-12-04+13.4%newssimplywall.stIndividual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st
2026-04-01+13.2%earningsMarketBeatAardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
2026-03-24-13.1%analystInvesting.comJones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com
2026-03-24-13.1%analystInvesting.comCantor Fitzgerald reiterates Aardvark Therapeutics stock rating - Investing.com
2026-03-24-13.1%newsTipRanksAardvark Therapeutics Establishes $150 Million Equity Program - TipRanks
2026-04-17+12.2%newsSimply Wall St.Discover 3 Promising Penny Stocks With Market Caps Over $100M
2026-04-17+12.2%newsTradingViewAARD Stock Price and Chart — NASDAQ:AARD - TradingView
2025-05-15+12.0%earningsSeeking AlphaAardvark Therapeutics reports Q1 results
2025-08-13+11.8%earningsSeeking AlphaAardvark Therapeutics GAAP EPS of -$0.66
2025-08-13+11.8%legalStock TitanAARD SEC Filings - Aardvark Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
2025-10-17-9.3%legalYahoo FinanceAardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment - Yahoo Finance
2026-03-23-8.1%newsMT NewswiresAardvark Therapeutics Files $400 Million Mixed Shelf
2026-03-23-8.1%newsGlobeNewswireAardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-23-8.1%earningsSeeking AlphaAardvark Therapeutics GAAP EPS of -$0.81 beats by $0.02
2026-03-23-8.1%newsStock TitanAardvark halts obesity and PWS studies after reversible heart findings - Stock Titan
2026-03-23-8.1%newsStock TitanAardvark Therapeutics (NASDAQ: AARD) halts ARD-101 and ARD-201 trials as 2025 loss widens - Stock Titan
2026-01-12+7.9%newsInvesting.comRaymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com
2026-01-12+7.9%newsTipRanksAardvark Therapeutics updates investor presentation on hunger therapies - TipRanks
2026-03-11-7.5%newsGlobeNewswireAardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
2025-03-10+6.3%newsChartMillAARD Income Statement | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
2025-12-12-6.1%executiveInvesting.comLee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com
2025-12-12-6.1%executiveInvesting.comSun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
2025-11-13-5.9%earningsSeeking AlphaAardvark Therapeutics GAAP EPS of -$0.75 beats by $0.08
2026-02-10-5.7%newsStock TitanDrug trial for rare Prader-Willi now open to U.S. kids 7+ - Stock Titan
2026-03-05+5.6%newsSimply Wall St.A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial
2026-03-05+5.6%newssimplywall.stA Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves - simplywall.st
2025-09-04+4.6%newsSeeking AlphaAardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript
2025-06-03+4.6%newsZacks Investment ResearchShould I buy Aardvark Therapeutics, Inc. (AARD) - Zacks Investment Research
2026-04-05-4.4%legalStock Titan[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
2026-04-03-4.4%newsStock TitanAardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - Stock Titan
2026-03-03+3.3%newssimplywall.stAardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101 - simplywall.st
2025-12-15-3.1%executivesimplywall.stInsider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
2026-02-12-3.0%executiveSeeking AlphaAardvark Therapeutics appoints Derrick C. Li as chief business officer
2026-04-23-2.9%analystChartMillAARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
2026-03-29+2.9%newsInsider MonkeyWhy Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
2026-03-29+2.9%newsYahoo FinanceWhy Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Yahoo Finance
2025-03-03-2.8%newsInsider MonkeyAardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
2025-03-01+1.8%newsChartMillAARD Stock Price, Quote & Chart | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
2025-02-16+1.7%newsintelligentinvestor.com.auAardvark Therapeutics Inc (NASDAQ: AARD) - Share Price - intelligentinvestor.com.au
2025-02-15+1.7%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2026-04-16+1.5%newsCổng thông tin điện tử tỉnh Tây NinhAardvark (AARD) Stock Mega Cap Focus (Trend Weakens) 2026-04-16 - Expert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
2026-04-11+0.8%newsTradingViewAARD Options Chain — NASDAQ:AARD - TradingView
2026-04-22-0.6%earningsCổng thông tin điện tử tỉnh Tây NinhAARD (Aardvark Therapeutics Inc.) posts narrower Q4 2025 loss than expected, sending shares nearly 5 percent higher. - Institutional Grade Picks - Cổng thông tin điện tử tỉnh Tây Ninh
2026-04-22-0.6%earningsXã Châu ThànhAARD (Aardvark) posts narrower than expected Q4 2025 loss, shares rise more than four percent today. - Real Trader Insights - Xã Châu Thành
2025-12-09+0.6%newsTradingKeyAARD|Aardvark Therapeutics Inc|Price:5.520|Chg%:0.15 - TradingKey
2026-04-09-0.3%newsGlobeNewswireAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
2025-11-25+0.2%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Aardvark Therapeutics, Inc. (AARD) - Zacks Investment Research
2026-03-12-0.0%newsPR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD - PR Newswire
2025-02-13—newsSeeking AlphaAardvark stock slides 11% following $94M IPO
2025-02-13—newsSeeking AlphaAardvark Therapeutics prices $94M IPO at $16 per share
2025-02-13—newsMedCity NewsAardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash - MedCity News
2025-02-13—analystTradingViewAARD Forecast — Price Target — Prediction for 2027 - TradingView
tickerdossier.comtickerdossier.substack.com